N
New Enterprise Associates, Inc.
+ HoldingSNTI
-16.14%
3M Return
$0.215
+0.033 (+15.21%)At close
Loading chart…
- High
- 0.231
- Open
- 0.181
- VWAP
- 0.21
- Volume
- 9.99M
- Mkt Cap
- 14.60M
- Low
- 0.181
- Amount
- 2.09M
- EV/EBITDA, TTM
- -0.57
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.
AI analysis of Senti Biosciences Holdings Inc (SNTI)
SellSenti Biosciences Inc is not a good buy right now due to significant financial losses and a very low RSI of 15.912, indicating oversold conditions. The company has reported a staggering year-to-date change of -82.87% and a one-year change of -91.59%, which reflects severe underperformance. The latest earnings report shows a Q1 2026 EPS of -0.14 and a revenue of only $0.01 million, raising concerns about its ability to generate income. Furthermore, the current price is $0.19, which is far below its historical highs, suggesting a lack of investor confidence and potential for further declines. The main risk is the ongoing operational losses, with a net income loss of -$12.75 million in Q2 2026, which could lead to liquidity issues and further stock depreciation.
Valuation Metrics
The current forward P/E ratio for Senti Biosciences Holdings Inc (SNTI) is 0.00, compared to its 5-year average forward P/E of -1.23.
Whales holding SNTI
Events Timeline
News
8.507-15seekingalphaSenti Biosciences to be Acquired by Celadon Affiliates, Focusing on New Technology
8.507-15NewsfilterSenti Biosciences Advances Controllable Cell and Gene Therapies
- 9.505-14seekingalpha
Senti Biosciences Reports Q1 2026 Financial Results
- 8.505-14Newsfilter
Senti Bio Advances SENTI-202 Registrational Trial Following FDA Meeting
- 9.503-27seekingalpha
Senti Biosciences Reports Q4 Losses, Misses EPS Estimates
SNTI FAQ — answered by Alphio AI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Senti Biosciences Inc is not a good buy right now due to significant financial losses and a very low RSI of 15.912, indicating oversold conditions. The company has reported a staggering year-to-date change of -82.87% and a one-year change of -91.59%, which reflects severe underperformance. The latest earnings report shows a Q1 2026 EPS of -0.14 and a revenue of only $0.01 million, raising concerns about its ability to generate income. Furthermore, the current price is $0.19, which is far below its historical highs, suggesting a lack of investor confidence and potential for further declines. The main risk is the ongoing operational losses, with a net income loss of -$12.75 million in Q2 2026, which could lead to liquidity issues and further stock depreciation.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.